Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Diagnostic imaging will become an increasingly vital process in healthcare
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Cipla and Ethris partner for the development of mRNA-based therapies
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
LG Chem will receive totaling up to $95.5 million for the China rights
Subscribe To Our Newsletter & Stay Updated